A $34.5 Million ARPA-H Push for Pediatric Gene Editing

The project seeks to move beyond the traditional "one-off" drug development model, which often fails to scale for rare disorders. By integrating advanced base and prime editing with specialized delivery techniques for the brain, the coalition aims to create a repeatable regulatory and scientific pathway. This architecture is designed to prove safety and efficacy in preclinical models, theoretically shortening the timeline between genetic discovery and human clinical trials.

Leading the preclinical efforts, the Rare Disease Translational Center at The Jackson Laboratory will leverage its established pipelines to validate these genetic corrections. The initiative, supported by the federal THRIVE program, brings together 12 institutions—including Boston Children's Hospital and the RARE Hope Foundation—to address the reality that nearly half of all rare genetic diseases impact the central nervous system. For children facing these conditions, the current standard of care remains stark, with many experiencing severe neurological decline before their fifth birthday.